natgillin/translations-raw huggingface dataset:
Iron oxide black (E172) 
črni železov oksid (E172)
Administration with a high-fat meal resulted in no change in total and peak exposure to alogliptin. 
Pri uporabi zdravila z obrokom z veliko vsebnostjo maščobe se skupna in največja izpostavljenost alogliptinu ni spremenila.
There have been post-marketing cases of cardiac failure reported when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure. 
V obdobju trženja so poročali o primerih srčnega popuščanja pri uporabi pioglitazona v kombinaciji z insulinom ali pri bolnikih s srčnim popuščanjem v anamnezi.
However, the results of bioequivalence studies have demonstrated that Incresync film-coated tablets are bioequivalent to the corresponding doses of alogliptin and pioglitazone co-administered as separate tablets. 
Vendar pa so rezultati študij bioekvivalence pokazali, da so filmsko obložene tablete zdravila Incresync bioekvivalentne ustreznim odmerkom alogliptina in pioglitazona, sočasno uporabljenim v obliki ločenih tablet.
Concomitant administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) or with rifampicin (an inducer of cytochrome P450 2C8) is reported to increase or decrease, respectively, the serum concentration of pioglitazone (see section 4.5). 
Za sočasno uporabo pioglitazona z gemfibrozilom (zaviralec citokroma P450 2C8) ali z rifampicinom (induktor citokroma P450 2C8) so poročali, da je prva kombinacija povečala, druga pa zmanjšala koncentracijo pioglitazona v serumu (glejte poglavje 4.5).
The pharmacokinetics of alogliptin in children and adolescents < 18 years old has not been established. 
Farmakokinetika alogliptina pri otrocih in mladostnikih, mlajših od 18 let, ni bila raziskana.
Effects of alogliptin on other medicinal products 
Učinki alogliptina na druga zdravila
There have been spontaneously reported adverse reactions of acute pancreatitis in the post-marketing setting. 
V obdobju trženja so bila pridobljena spontana poročila o pojavu akutnega pankreatitisa.
What Incresync is Incresync contains two different medicines called alogliptin and pioglitazone in one tablet: 
Zdravilo Incresync v eni tableti združuje dve različni zdravilni učinkovini, imenovani alogliptin in pioglitazon:
Iron oxide yellow (E172) 
rumeni železov oksid (E172)
In vitro studies indicate that alogliptin does not induce CYP1A2, CYP2B6 and CYP2C9 and does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4 at concentrations achieved with the recommended dose of 25 mg alogliptin. 
Študije in vitro kažejo, da alogliptin pri koncentracijah, doseženih s priporočenim odmerkom 25 mg alogliptina, ne inducira CYP1A2, CYP2B6 in CYP2C9 ter ne zavira CYP1A2, CYP2B6, CYP2C8,
Cardiac failure or history of cardiac failure (NYHA stages I to IV; see section 4.4) Hepatic impairment (see section 4.4) 
• Srčno popuščanje ali anamneza srčnega popuščanja (razredi I do IV po NYHA, glejte poglavje 4.4).
The addition of 25 mg alogliptin once daily to pioglitazone therapy (mean dose = 35.0 mg, with or without metformin or a sulphonylurea) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 2). 
Alogliptin kot dodatek k zdravljenju s pioglitazonom Dodatek alogliptina v odmerku 25 mg enkrat na dan k zdravljenju s pioglitazonom (povprečni odmerek = 35,0 mg, v kombinaciji z metforminom ali s sulfonilsečnino ali brez) je v 26. tednu povzročil statistično pomembna izboljšanja glede na izhodiščne vrednosti HbA1c in vrednosti glukoze v plazmi na tešče v primerjavi z dodatkom placeba (tabela 2).
If pancreatitis is suspected, Incresync should be discontinued; if acute pancreatitis is confirmed, Incresync should not be restarted. 
Če je akutno vnetje trebušne slinavke potrjeno, se zdravljenja z zdravilom Incresync ne sme več uvesti.
Incresync is not a substitute for insulin in insulin-requiring patients. 
Pri bolnikih, ki potrebujejo zdravljenje z insulinom, zdravilo Incresync ne more nadomestiti insulina.
In the 3.5 year cardiovascular risk PROactive study, 44/870 (5.1%; 1.0 fractures per 100 patient years) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%; 0.5 fractures per 100 patient years) of female patients treated with comparator. 
V 3,5-letni študiji kardiovaskularnega tveganja PROactive so o zlomu poročali pri 44 od 870 žensk, ki so se zdravile s pioglitazonom (5,1 %, 1,0 zloma na 100 bolnikov-let), in pri 23 od 905 žensk, ki so prejemale primerjalno zdravilo (2,5 %, 0,5 zloma na 100 bolnikov-let).
A pooled analysis was conducted of adverse reactions of bone fractures from randomised, comparator-controlled, double-blind clinical studies in over 8,100 patients in the pioglitazone-treated groups and 7,400 in the comparator-treated groups of up to 3.5 years duration. 
Izvedena je bila združena analiza neželenih učinkov v obliki zlomov kosti iz randomiziranih, s primerjalnim zdravilom nadzorovanih, dvojno slepih kliničnih študij, ki so trajala do 3,5 let in zajela več kot 8.100 bolnikov, ki so se zdravili s pioglitazonom, in 7.400 bolnikov, ki so se zdravili s primerjalnim zdravilom.
Clinical studies conducted to support the efficacy and safety of Incresync involved the co-administration of alogliptin and pioglitazone as separate tablets. 
Klinične študije, izvedene z namenom ugotovitve učinkovitosti in varnosti zdravila Incresync, so vrednotile sočasno uporabo alogliptina in pioglitazona v obliki ločenih tablet.
In a pooled analysis of the data from 12 studies, the overall incidence of any episode of hypoglycaemia was lower in patients treated with 25 mg alogliptin than in patients treated with 12.5 mg alogliptin, active-control or placebo (3.6%, 4.6%, 12.9% and 6.2%, respectively). 
V združeni analizi podatkov iz 12 študij je bila skupna pojavnost kakršne koli epizode hipoglikemije manjša pri bolnikih, zdravljenih z alogliptinom v odmerku 25 mg (3,6 %), kot pri bolnikih, zdravljenih z alogliptinom v odmerku 12,5 mg (4,9 %), s kontrolnim zdravilom (12,9 %) ali placebom (6,2 %).
Nervous system disorders headache common common hypoaesthesia common insomnia uncommon 
Bolezni živčevja glavobol pogosti pogosti hipestezija pogosti nespečnost občasni
Rare cases of elevated liver enzymes and hepatocellular dysfunction have occurred in post-marketing experience. 
V obdobju trženja so poročali o redkih primerih zvišanja vrednosti jetrnih encimov in hepatocelularne disfunkcije.
Incresync 12.5 mg/30 mg film-coated tablets Incresync 12.5 mg/45 mg film-coated tablets Incresync 25 mg/30 mg film-coated tablets Incresync 25 mg/45 mg film-coated tablets 
Incresync 12,5 mg/30 mg filmsko obložene tablete Incresync 12,5 mg/45 mg filmsko obložene tablete Incresync 25 mg/30 mg filmsko obložene tablete Incresync 25 mg/45 mg filmsko obložene tablete
In clinical studies of up to two years duration, pioglitazone reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels compared to placebo, metformin or gliclazide. 
V kliničnih študijah, ki so trajale do dve leti, je pioglitazon v primerjavi s placebom, z metforminom ali gliklazidom znižal celotno koncentracijo plazemskih trigliceridov in prostih maščobnih kislin v plazmi ter povečal koncentracijo holesterola HDL.
Therefore, one tablet of 12.5 mg/30 mg or 12.5 mg/45 mg once daily, depending on the dose of pioglitazone already being taken, is recommended in patients with moderate renal impairment (see section 5.2). 
Pri bolnikih z zmerno okvaro ledvic je tako priporočena uporaba ene tablete 12,5 mg/30 mg ali 12,5 mg/45 mg enkrat na dan, odvisno od odmerka pioglitazona, ki ga že jemljejo (glejte poglavje 5.2).
Significantly more patients receiving 25 mg alogliptin plus 30 mg pioglitazone and metformin (33.2%) achieved target HbA1c levels of ≤ 7.0% compared to those receiving 45 mg pioglitazone and metformin (21.3%) at Week 52 (p<0.001). 
V 52. tednu je ciljne vrednosti HbA1c ≤ 7,0 % doseglo pomembno več bolnikov, ki so prejemali alogliptin v odmerku 25 mg v kombinaciji s 30 mg pioglitazona in z metforminom (33,2 %), v primerjavi z bolniki, ki so prejemali 45 mg pioglitazona in metformin (21,3 %) (p<0,001).
Patients should, therefore, be made aware of the risk of pregnancy and if a patient wishes to become pregnant or if pregnancy occurs, Incresync treatment should be discontinued (see section 4.6). 
Če bolnica želi zanositi ali če zanosi, je treba zdravljenje z zdravilom Incresync prekiniti (glejte poglavje 4.6).
The decision whether to continue the patient on therapy with Incresync should be guided by clinical judgement pending laboratory evaluations. 
Dokler laboratorijski izvidi niso na voljo, se je o nadaljevanju zdravljenja z zdravilom Incresync treba odločiti po klinični presoji.
INFORMATION IN BRAILLE Incresync 25 mg/45 mg 
PODATKI V BRAILLOVI PISAVI Incresync 25 mg/45 mg
Other reactions such as upper respiratory tract infections, sinusitis, headache, hypoglycaemia, nausea, weight increase and oedema may occur commonly (≥ 1/100 to 
Pogosto (≥ 1/100 do < 1/10) se lahko pojavijo druge reakcije, kot so okužbe zgornjih dihal, sinuzitis, glavobol, hipoglikemija, navzea, povečanje telesne mase in edemi.
Due to its pioglitazone component, Incresync should not be used in patients with hepatic impairment (see section 4.2). 
Pri bolnikih z okvaro jeter se zdravila Incresync zaradi vsebnosti pioglitazona ne sme uporabljati (glejte poglavje 4.2).
These patients may be at risk of pregnancy. 
Pri takšnih bolnicah lahko obstaja možnost zanositve.
Co-administration of pioglitazone with rifampicin (an inducer of cytochrome P450 2C8) is reported to result in a 54% decrease in AUC for pioglitazone. 
Poročali so, da se je pri sočasni uporabi pioglitazona in rifampicina (induktor citokroma P450 2C8) vrednost AUC pioglitazona zmanjšala za 54 %.
- If you get any side effects, talk to your doctor or pharmacist. 
- Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom ali s farmacevtom.
Incresync 12.5 mg/30 mg film-coated tablets Incresync 12.5 mg/45 mg film-coated tablets Incresync 25 mg/30 mg film-coated tablets Incresync 25 mg/45 mg film-coated tablets alogliptin/pioglitazone 
Incresync 12,5 mg/30 mg filmsko obložene tablete Incresync 12,5 mg/45 mg filmsko obložene tablete Incresync 25 mg/30 mg filmsko obložene tablete Incresync 25 mg/45 mg filmsko obložene tablete alogliptin/pioglitazon
The pharmacokinetics of pioglitazone in children and adolescents < 18 years old has not been established. 
Farmakokinetika pioglitazona pri otrocih in mladostnikih, mlajših od 18 let, ni bila raziskana.
Clinical studies conducted to support the efficacy of Incresync involved the co-administration of alogliptin and pioglitazone as separate tablets. 
Klinične študije, izvedene z namenom ugotovitve učinkovitosti zdravila Incresync, so vrednotile sočasno uporabo alogliptina in pioglitazona v obliki ločenih tablet.
An approximate 1.7-fold increase in AUC for alogliptin was observed in patients with mild renal impairment. 
Pri bolnikih z blago okvaro ledvic je bilo opaženo približno 1,7-kratno povečanje vrednosti AUC alogliptina.
No dose adjustment of Incresync for patients with mild renal impairment is necessary (see section 4.2). 
Pri bolnikih z blago okvaro ledvic odmerka zdravila Incresync ni treba prilagajati (glejte poglavje 4.2).
Incresync should be discontinued if any deterioration in cardiac status occurs. 
Če se pojavi kakršno koli poslabšanje srčnega statusa, je treba zdravljenje z zdravilom Incresync prekiniti.
Common: - Symptoms of low blood sugar (hypoglycaemia) may occur when Incresync is taken in combination with insulin or sulphonylureas (e.g. glipizide, tolbutamide, glibenclamide). 
Incresync jemljete skupaj z insulinom ali s sulfonilsečninami (npr. glipizid, tolbutamid,
Marketing Authorisation Holder Takeda Pharma A/S Dybendal Alle 10 
Imetnik dovoljenja za promet z zdravilom Takeda Pharma A/S
INFORMATION IN BRAILLE Incresync 12.5 mg/45 mg 
PODATKI V BRAILLOVI PISAVI Incresync 12,5 mg/45 mg
A higher rate of fractures was observed in women taking pioglitazone (2.6%) versus comparator (1.7%). 
Večji delež zlomov so opazili pri ženskah, ki so prejemale pioglitazon (2,6 %), kot pri ženskah, ki so prejemale primerjalno zdravilo (1,7 %).
INFORMATION IN BRAILLE Incresync 12.5 mg/30 mg 
PODATKI V BRAILLOVI PISAVI Incresync 12,5 mg/30 mg
Warnings and precautions Talk to your doctor or pharmacist before taking Incresync: - if you have type 1 diabetes (your body does not produce insulin). 
• če imate sladkorno bolezen tipa 1 (telo ne proizvaja insulina).
Infections and infestations upper respiratory tract infections common common common nasopharyngitis common sinusitis uncommon common 
Infekcijske in parazitske bolezni okužbe zgornjih dihal pogosti pogosti pogosti nazofaringitis pogosti sinuzitis občasni pogosti
Foetal growth restriction was apparent in animal studies with pioglitazone. 
V študijah pioglitazona na živalih so opazili omejitev rasti plodov.
Current bladder cancer or a history of bladder cancer (see section 4.4) Uninvestigated macroscopic haematuria (see section 4.4) 
• Trenutni rak sečnega mehurja ali rak sečnega mehurja v anamnezi (glejte poglavje 4.4).
INFORMATION IN BRAILLE Incresync 25 mg/30 mg 
PODATKI V BRAILLOVI PISAVI Incresync 25 mg/30 mg
Metabolism and nutrition disorders hypoglycaemia common common 
Presnovne in prehranske motnje hipoglikemija pogosti pogosti
Incresync may, therefore, be administered with or without food. 
Zdravilo Incresync se tako lahko jemlje s hrano ali brez nje.
Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh score > 9). 
Pri bolnikih s hudo okvaro jeter (ocena po Child-Pugh-u > 9) uporabe alogliptina niso raziskovali.
Placebo-corrected change from baseline in HbA1c (%)† 
S placebom korigirana sprememba vrednosti HbA1c od izhodišča (%)† (2-stranski 95 % IZ)
You may experience visual disturbances while taking this medicine. 
Vpliv na sposobnost upravljanja vozil in strojev Med jemanjem tega zdravila se lahko pojavijo motnje vida.
- Liver problems such as nausea or vomiting, stomach pain, unusual or unexplained tiredness, 
• Težave z jetri, kot so siljenje na bruhanje, bruhanje, bolečina v trebuhu, neobičajna ali nepojasnjena utrujenost, izguba apetita, temen urin ali rumeno obarvanje kože ali očesnih beločnic.
Incresync contains lactose 
Zdravilo Incresync vsebuje laktozo
- if you have heart failure or have had heart failure in the past. 
• če imate ali ste kdaj imeli srčno popuščanje.
Alogliptin as add-on therapy to pioglitazone with metformin The addition of 25 mg alogliptin once daily to 30 mg pioglitazone in combination with metformin hydrochloride therapy (mean dose = 1,867.9 mg) resulted in improvements from baseline in HbA1c at Week 52 that were both non-inferior and statistically superior to those produced by 45 mg pioglitazone in combination with metformin hydrochloride therapy (mean dose = 1,847.6 mg, Table 3). 
Alogliptin kot dodatek k zdravljenju s pioglitazonom in z metforminom Dodatek alogliptina v odmerku 25 mg enkrat na dan k zdravljenju s 30 mg pioglitazona in z metforminijevim kloridom (povprečni odmerek = 1.867,9 mg) je v 52. tednu povzročil izboljšanja glede na izhodiščne vrednosti HbA1c.
How to store Incresync 
Shranjevanje zdravila Incresync
Incresync 25 mg/45 mg film-coated tablets 
Incresync 25 mg/45 mg filmsko obložene tablete
There is no experience of using Incresync in pregnant women or during breast-feeding. 
Pri nosečnicah ali doječih materah ni izkušenj z uporabo zdravila Incresync.
Uncommon (may affect up to 1 in 100 people): - Symptoms of bladder cancer including blood in your urine, pain when urinating or a sudden need to urinate. 
• Simptomi raka sečnega mehurja, vključno s krvjo v urinu, bolečino med uriniranjem ali nenadno potrebo po uriniranju.
25 mg/30 mg film-coated tablets 
25 mg/30 mg filmsko obložene tablete
After administration of single, oral doses of up to 800 mg in healthy subjects, alogliptin was rapidly absorbed with peak plasma concentrations occurring 1 to 2 hours (median Tmax) after dosing. 
Največje koncentracije v plazmi so bile dosežene 1 do 2 uri (mediana vrednost Tmax) po odmerku.
12.5 mg/45 mg film-coated tablets 
12,5 mg/45 mg filmsko obložene tablete
Red, round (approximately 8.7 mm in diameter), biconvex, film-coated tablets with both “A/P” and “25/45” printed in grey ink on one side. 
Okrogle (premer približno 8,7 mm), bikonveksne, filmsko obložene tablete rdeče barve z odtisnjenima sivima oznakama “A/P” in “25/45” na eni strani.
However, dosing of alogliptin should be conservative in patients with advanced age due to the potential for decreased renal function in this population. 
Odmerka glede na starost ni treba prilagajati (glejte poglavje 4.4), vendar pa je pri bolnikih z višjo starostjo treba alogliptin odmerjati previdno, saj pri tej populaciji bolnikov obstaja tveganje za oslabljeno delovanje ledvic.
A cardiovascular outcome study of pioglitazone has been performed in patients under 75 years with type 2 diabetes mellitus and pre-existing major macrovascular disease. 
Pri bolnikih, mlajših od 75 let, s sladkorno boleznijo tipa 2 in že obstoječo hujšo makrovaskularno boleznijo, so izvedli študijo kardiovaskularnega izida zdravljenja s pioglitazonom.
What Incresync looks like and contents of the pack - Incresync 25 mg/30 mg film-coated tablets (tablets) are peach, round (approximately 8.7 mm in diameter), biconvex, film-coated tablets, with both “A/P” and “25/30” printed in grey ink on one side. 
Izgled zdravila Incresync in vsebina pakiranja - Incresync 25 mg/30 mg filmsko obložene tablete (tablete) so okrogle (premer približno 8,7 mm), obojestransko izbočene, filmsko obložene tablete breskove barve z odtisnjenima sivima oznakama “A/P” in “25/30” na eni strani.
Printing ink 12.5 mg/30 mg film-coated tablets 
Črnilo za tisk 12,5 mg/30 mg filmsko obložene tablete
12.5 mg/30 mg film-coated tablets 
12,5 mg/30 mg filmsko obložene tablete
Proportional increases of the serum concentration were observed for doses from 2-60 mg. Steady-state is achieved after 4-7 days of dosing. 
Pri odmerkih od 2 do 60 mg so opazili sorazmerna povečanja koncentracije v serumu.
Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone. 
Pri tiazolidindionih, vključno s pioglitazonom, so v obdobju trženja poročali o novo nastalem diabetičnem makularnem edemu ali njegovem poslabšanju z zmanjšanjem ostrine vida.
Incresync is not recommended for children and adolescents under 18 years due to the lack of data in these patients. 
Zaradi pomanjkanja podatkov uporaba zdravila Incresync pri otrocih in mladostnikih, mlajših od 18 let, ni priporočljiva.
Treatment-corrected change from baseline in HbA1c (%)† 
Z zdravilom korigirana sprememba vrednosti HbA1c od izhodišča (%)† (1-stranski IZ)
Appropriate assessment of renal function is recommended prior to initiation of Incresync and periodically thereafter (see section 4.4). 
Pred uvedbo zdravljenja z zdravilom Incresync in v rednih časovnih presledkih med zdravljenjem priporočamo izvedbo ustreznih preiskav za oceno delovanja ledvic (glejte poglavje 4.4).
No increase in fracture rates was observed in men treated with pioglitazone (1.7%) versus comparator (2.1%). 
Pri moških, ki so prejemali pioglitazon, delež zlomov ni bil večji (1,7 %) kot pri moških, ki so prejemali primerjalno zdravilo (2,1 %).
Postmarketing reports of hepatic dysfunction including hepatic failure have been received for alogliptin. 
V obdobju trženja so bila spontana poročila o takšnih reakcijah pridobljena tudi za alogliptin.
- Incresync 25 mg/45 mg film-coated tablets (tablets) are red, round (approximately 8.7 mm in diameter), biconvex, film-coated tablets, with both “A/P” and “25/45” printed in grey ink on one side. 
- Incresync 25 mg/45 mg filmsko obložene tablete (tablete) so okrogle (premer približno 8,7 mm), obojestransko izbočene, filmsko obložene tablete rdeče barve z odtisnjenima sivima oznakama “A/P” in “25/45” na eni strani.
Fasting and postprandial glycaemic control is improved following treatment with pioglitazone in patients with type 2 diabetes mellitus. 
Zdravljenje s pioglitazonom pri bolnikih s sladkorno boleznijo tipa 2 izboljša urejenost glikemije na tešče in po obroku.
and lower than the incidence in patients treated with active-control or placebo (0.1%, 0.1%, 0.4% and 0.4%, respectively). 
Celotna pojavnost epizod hude hipoglikemije je bila pri bolnikih, zdravljenih z alogliptinom v odmerku 25 mg (0,1 %) ali 12,5 mg (0,1 %) primerljiva in manjša od pojavnosti pri bolnikih, zdravljenih s kontrolnim zdravilom (0,4 %) ali placebom (0,4 %).
Hypersensitivity reactions, including anaphylactic reactions, angioedema and exfoliative skin conditions including Stevens-Johnson syndrome and erythema multiforme have been observed for DPP-4 inhibitors and have been spontaneously reported for alogliptin in the post-marketing setting. 
Pri uporabi zaviralcev DPP-4 so poročali o pojavu preobčutljivostnih reakcij, vključno z anafilaktičnimi reakcijami, angioedemom in eksfoliativnimi kožnimi boleznimi, vključno s Stevens-Johnsonovim sindromom in multiformnim eritemom.
An increased incidence of hyperplasia (males and females) and tumours (males) of the urinary bladder epithelium was apparent in rats treated with pioglitazone for up to 2 years. 
Pri podganah, ki so prejemale pioglitazon do 2 leti, so opažali večjo pojavnost hiperplazije (samci in samice) ter tumorjev (samci) epitelija sečnega mehurja.
Each 25 mg/45 mg film-coated tablet contains alogliptin benzoate and pioglitazone hydrochloride equivalent to 25 mg alogliptin and 45 mg pioglitazone. 
Ena 25 mg/45 mg filmsko obložena tableta vsebuje alogliptinijev benzoat in pioglitazonijev klorid v količini, ki ustreza 25 mg alogliptina in 45 mg pioglitazona.
Co-administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) is reported to result in a 3-fold increase in AUC for pioglitazone. 
Poročali so, da se je pri sočasni uporabi pioglitazona in gemfibrozila (zaviralec citokroma P450 2C8) vrednosti AUC pioglitazona povečala za 3-krat.
NAME OF THE MEDICINAL PRODUCT Incresync 25 mg/45 mg tablets alogliptin/pioglitazone 
IME ZDRAVILA Incresync 25 mg/45 mg tablete alogliptin/pioglitazon
Incresync is not recommended for patients with severe renal impairment or end-stage renal disease requiring dialysis (see section 4.2). 
Pri bolnikih s hudo okvaro ledvic in bolnikih s končno ledvično odpovedjo, ki potrebujejo zdravljenje z dializo, uporaba zdravila Incresync ni priporočljiva (glejte poglavje 4.2).
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 25 mg alogliptin (as benzoate) and 45 mg pioglitazone (as hydrochloride). 
NAVEDBA ENE ALI VEČ UČINKOVIN Ena tableta vsebuje 25 mg alogliptina (v obliki benzoata) in 45 mg pioglitazona (v obliki klorida).
Each 12.5 mg/45 mg film-coated tablet contains alogliptin benzoate and pioglitazone hydrochloride equivalent to 12.5 mg alogliptin and 45 mg pioglitazone. 
Ena 12,5 mg/45 mg filmsko obložena tableta vsebuje alogliptinijev benzoat in pioglitazonijev klorid v količini, ki ustreza 12,5 mg alogliptina in 45 mg pioglitazona.
Your blood sugar levels may increase when you stop taking Incresync. 
Po prenehanju jemanja zdravila Incresync se vrednost krvnega sladkorja lahko zviša.
- Incresync 12.5 mg/45 mg film-coated tablets (tablets) are pale red, round (approximately 8.7 mm in diameter), biconvex, film-coated tablets, with both “A/P” and “12.5/45” printed in red ink on one side. 
- Incresync 12,5 mg/45 mg filmsko obložene tablete (tablete) so okrogle (premer približno 8,7 mm), obojestransko izbočene, filmsko obložene tablete svetlo rdeče barve z odtisnjenima rdečima oznakama “A/P” in “12.5/45” na eni strani.
- Incresync 12.5 mg/30 mg film-coated tablets (tablets) are pale peach, round (approximately 8.7 mm in diameter), biconvex, film-coated tablets, with both “A/P” and “12.5/30” printed in red ink on one side. 
- Incresync 12,5 mg/30 mg filmsko obložene tablete (tablete) so okrogle (premer približno 8,7 mm), obojestransko izbočene, filmsko obložene tablete svetle breskove barve z odtisnjenima rdečima oznakama “A/P” in “12.5/30” na eni strani.